Breast Health

Latest News



Recent studies have indicated that β-adrenergic signaling is involved in the regulation of immune responses to breast tumor cells, and data from in vivo studies show an association between β-adrenergic signaling with increased nodal involvement and development of metastasis but no effect on primary tumor growth. Based on this evidence, Dr Thomas I. Barron, from the department of pharmacology and therapeutics at Trinity Centre for Health Sciences, in Dublin, Ireland, and colleagues chose to explore the relationship between beta blocker use and breast tumor characteristics as well as breast cancer morbidity.

Breast cancer is a growing concern among premenopausal women. With an emphasis on this patient population, this article discusses the known risk factors for breast cancer; models for quantitative risk assessment; and strategies for modifying breast cancer risk, including screening mammography, prophylactic mastectomy, and primary pharmacologic prevention.

A report just published in the Journal of the American Medical Association confirmed previous studies which found that women who take hormone replacement therapy (HRT) may develop denser breast tissue, which in turn may make it more difficult to detect breast cancer through mammography.

FDA approval for bevacizumab (Avastin) as treatment for metastatic HER2-negative breast cancer should be withdrawn, according to a unanimous vote (6-0) of the FDA’s Oncologic Drug Advisory Committee. The committee convened at the request of the drugmaker (Genentech) to appeal an earlier decision by the FDA to remove the indication for bevacizumab to treat locally recurrent or metastatic HER2-negative breast cancer.

The FDA recently approved a new genetic test, called Inform Dual ISH, that helps determine whether women with breast cancer have the human epidermal growth factor receptor 2 (HER2)-positive type.1 In about 20% of breast cancers, the cancer cells produce an excess of the protein HER2 because of a gene mutation. HER2-positive breast cancers tend to be more aggressive and respond less well to hormone therapy.

One in nine women will develop breast cancer during her lifetime, provided she lives to age 85. Most breast cancer is NOT genetically linked – less than 16%. In the study by Stavros et al., July 1995, – over 80% of all sonographic, biopsy proven, solid nodules were benign.

Consumption of food containing soy isoflavones does not appear to increase the risk of cancer recurrence or mortality among breast cancer survivors, according to research presented at the annual meeting of the American Association for Cancer Research, held April 2 to 6 in Orlando, Fla.

Among postmenopausal women with prior hysterectomy, cessation of conjugated equine estrogen (CEE) therapy reduces the risk of stroke, and the risk of breast cancer remains reduced, according to a study to be published on April 6 in the Journal of the American Medical Association.

An individualized screen evaluating epithelial cells from women's breast milk may provide insight into breast cancer risk, according to research presented at the annual meeting of the American Association for Cancer Research, held April 2 to 6 in Orlando, Fla.

Concern that risks outweighed the possible benefits of estrogen use caused the cessation of the Women's Health Initiative Estrogen-Alone Trial. However, researchers decided to continue monitoring patients for outcomes despite the study protocol discontinuation to gain insight into the long-term effects of the conjugated equine estrogens (CEE) therapy. What they found was surprising-and somewhat positive.

Advanced stages at presentation, and limited diagnostic and treatment capabilities, contribute to lower breast cancer survival in low-income and middle-income countries (LMC), according to the executive summary of the Breast Health Global Initiative Consensus 2010, published in the April issue of The Lancet Oncology.

Using a combination of magnetic resonance (MR) imaging and mammography increases sensitivity of cancer detection in women with a history of chest irradiation compared to using either modality on its own, according to a study published in the April issue of Radiology.n

Pacifier use in healthy, full-term newborns, introduced before or after breast-feeding is established, has little impact on the prevalence or duration of breast-feeding up to four months, according to a review published online in the Cochrane Database of Systematic Reviews.